ARDENT HEALTH INC (ARDT) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:ARDT - US03980N1072 - Common Stock
8.89 USD
-0.04 (-0.45%)
Taking everything into account, ARDT scores 6 out of 10 in our fundamental rating. ARDT was compared to 101 industry peers in the Health Care Providers & Services industry. ARDT has an average financial health and profitability rating. ARDT may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make ARDT suitable for value investing!
1. Profitability
1.1 Basic Checks
ARDT had positive earnings in the past year.
In the past year ARDT had a positive cash flow from operations.
1.2 Ratios
ARDT has a better Return On Assets (3.98%) than 71.29% of its industry peers.
ARDT has a better Return On Equity (16.56%) than 85.15% of its industry peers.
Looking at the Return On Invested Capital, with a value of 7.53%, ARDT is in the better half of the industry, outperforming 70.30% of the companies in the same industry.
ARDT had an Average Return On Invested Capital over the past 3 years of 5.96%. This is below the industry average of 9.22%.
The last Return On Invested Capital (7.53%) for ARDT is above the 3 year average (5.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.98% | ||
| ROE | 16.56% | ||
| ROIC | 7.53% |
ROA(3y)3.2%
ROA(5y)N/A
ROE(3y)18.73%
ROE(5y)N/A
ROIC(3y)5.96%
ROIC(5y)N/A
1.3 Margins
ARDT has a better Profit Margin (3.24%) than 69.31% of its industry peers.
ARDT's Profit Margin has improved in the last couple of years.
The Operating Margin of ARDT (5.98%) is better than 65.35% of its industry peers.
In the last couple of years the Operating Margin of ARDT has grown nicely.
The Gross Margin of ARDT (57.94%) is better than 80.20% of its industry peers.
ARDT's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.98% | ||
| PM (TTM) | 3.24% | ||
| GM | 57.94% |
OM growth 3Y3%
OM growth 5YN/A
PM growth 3Y3.64%
PM growth 5YN/A
GM growth 3Y2.83%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ARDT is destroying value.
Compared to 1 year ago, ARDT has more shares outstanding
The debt/assets ratio for ARDT has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.03 indicates that ARDT is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ARDT (2.03) is comparable to the rest of the industry.
The Debt to FCF ratio of ARDT is 7.03, which is on the high side as it means it would take ARDT, 7.03 years of fcf income to pay off all of its debts.
ARDT's Debt to FCF ratio of 7.03 is in line compared to the rest of the industry. ARDT outperforms 58.42% of its industry peers.
A Debt/Equity ratio of 0.88 indicates that ARDT is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.88, ARDT is in line with its industry, outperforming 42.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.88 | ||
| Debt/FCF | 7.03 | ||
| Altman-Z | 2.03 |
ROIC/WACC0.9
WACC8.41%
2.3 Liquidity
ARDT has a Current Ratio of 2.08. This indicates that ARDT is financially healthy and has no problem in meeting its short term obligations.
ARDT's Current ratio of 2.08 is amongst the best of the industry. ARDT outperforms 80.20% of its industry peers.
A Quick Ratio of 1.95 indicates that ARDT should not have too much problems paying its short term obligations.
ARDT has a Quick ratio of 1.95. This is amongst the best in the industry. ARDT outperforms 81.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.08 | ||
| Quick Ratio | 1.95 |
3. Growth
3.1 Past
ARDT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 314.38%, which is quite impressive.
Measured over the past years, ARDT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.75% on average per year.
Looking at the last year, ARDT shows a quite strong growth in Revenue. The Revenue has grown by 10.29% in the last year.
Measured over the past years, ARDT shows a small growth in Revenue. The Revenue has been growing by 7.00% on average per year.
EPS 1Y (TTM)314.38%
EPS 3Y13.75%
EPS 5YN/A
EPS Q2Q%205.88%
Revenue 1Y (TTM)10.29%
Revenue growth 3Y7%
Revenue growth 5YN/A
Sales Q2Q%8.75%
3.2 Future
The Earnings Per Share is expected to grow by 21.62% on average over the next years. This is a very strong growth
Based on estimates for the next years, ARDT will show a small growth in Revenue. The Revenue will grow by 7.17% on average per year.
EPS Next Y52.55%
EPS Next 2Y26.02%
EPS Next 3Y21.62%
EPS Next 5YN/A
Revenue Next Year8.59%
Revenue Next 2Y6.75%
Revenue Next 3Y6.44%
Revenue Next 5Y7.17%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 4.15, the valuation of ARDT can be described as very cheap.
Based on the Price/Earnings ratio, ARDT is valued cheaply inside the industry as 99.01% of the companies are valued more expensively.
ARDT is valuated cheaply when we compare the Price/Earnings ratio to 26.37, which is the current average of the S&P500 Index.
ARDT is valuated cheaply with a Price/Forward Earnings ratio of 4.55.
ARDT's Price/Forward Earnings ratio is rather cheap when compared to the industry. ARDT is cheaper than 98.02% of the companies in the same industry.
ARDT is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.20, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.15 | ||
| Fwd PE | 4.55 |
4.2 Price Multiples
97.03% of the companies in the same industry are more expensive than ARDT, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ARDT indicates a rather cheap valuation: ARDT is cheaper than 89.11% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.08 | ||
| EV/EBITDA | 3.34 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ARDT may justify a higher PE ratio.
A more expensive valuation may be justified as ARDT's earnings are expected to grow with 21.62% in the coming years.
PEG (NY)0.08
PEG (5Y)N/A
EPS Next 2Y26.02%
EPS Next 3Y21.62%
5. Dividend
5.1 Amount
No dividends for ARDT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:ARDT (12/4/2025, 11:15:31 AM)
8.89
-0.04 (-0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners73.82%
Inst Owner Change2.1%
Ins Owners1.98%
Ins Owner Change-0.01%
Market Cap1.27B
Revenue(TTM)6.33B
Net Income(TTM)205.06M
Analysts80
Price Target16.58 (86.5%)
Short Float %2.5%
Short Ratio5.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.03%
Min EPS beat(2)24.85%
Max EPS beat(2)71.2%
EPS beat(4)4
Avg EPS beat(4)53.83%
Min EPS beat(4)24.85%
Max EPS beat(4)76.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.13%
Min Revenue beat(2)-0.08%
Max Revenue beat(2)4.33%
Revenue beat(4)2
Avg Revenue beat(4)2.08%
Min Revenue beat(4)-2.01%
Max Revenue beat(4)6.1%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.47%
PT rev (3m)-17.51%
EPS NQ rev (1m)-33.4%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0.19%
Revenue NQ rev (1m)-1.95%
Revenue NQ rev (3m)-2.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.15 | ||
| Fwd PE | 4.55 | ||
| P/S | 0.2 | ||
| P/FCF | 8.08 | ||
| P/OCF | 3.47 | ||
| P/B | 1.03 | ||
| P/tB | 4.7 | ||
| EV/EBITDA | 3.34 |
EPS(TTM)2.14
EY24.07%
EPS(NY)1.95
Fwd EY21.97%
FCF(TTM)1.1
FCFY12.37%
OCF(TTM)2.56
OCFY28.8%
SpS44.18
BVpS8.65
TBVpS1.89
PEG (NY)0.08
PEG (5Y)N/A
Graham Number20.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.98% | ||
| ROE | 16.56% | ||
| ROCE | 8.99% | ||
| ROIC | 7.53% | ||
| ROICexc | 8.81% | ||
| ROICexgc | 12.04% | ||
| OM | 5.98% | ||
| PM (TTM) | 3.24% | ||
| GM | 57.94% | ||
| FCFM | 2.49% |
ROA(3y)3.2%
ROA(5y)N/A
ROE(3y)18.73%
ROE(5y)N/A
ROIC(3y)5.96%
ROIC(5y)N/A
ROICexc(3y)6.85%
ROICexc(5y)N/A
ROICexgc(3y)9.47%
ROICexgc(5y)N/A
ROCE(3y)7.12%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y3%
OM growth 5YN/A
PM growth 3Y3.64%
PM growth 5YN/A
GM growth 3Y2.83%
GM growth 5YN/A
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.88 | ||
| Debt/FCF | 7.03 | ||
| Debt/EBITDA | 2.05 | ||
| Cap/Depr | 137.15% | ||
| Cap/Sales | 3.31% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 69.06% | ||
| Profit Quality | 76.79% | ||
| Current Ratio | 2.08 | ||
| Quick Ratio | 1.95 | ||
| Altman-Z | 2.03 |
F-Score8
WACC8.41%
ROIC/WACC0.9
Cap/Depr(3y)111.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.88%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)314.38%
EPS 3Y13.75%
EPS 5YN/A
EPS Q2Q%205.88%
EPS Next Y52.55%
EPS Next 2Y26.02%
EPS Next 3Y21.62%
EPS Next 5YN/A
Revenue 1Y (TTM)10.29%
Revenue growth 3Y7%
Revenue growth 5YN/A
Sales Q2Q%8.75%
Revenue Next Year8.59%
Revenue Next 2Y6.75%
Revenue Next 3Y6.44%
Revenue Next 5Y7.17%
EBIT growth 1Y87.99%
EBIT growth 3Y10.2%
EBIT growth 5YN/A
EBIT Next Year68.59%
EBIT Next 3Y25.08%
EBIT Next 5YN/A
FCF growth 1Y51.28%
FCF growth 3Y152.66%
FCF growth 5YN/A
OCF growth 1Y42.1%
OCF growth 3Y28.95%
OCF growth 5YN/A
ARDENT HEALTH INC / ARDT FAQ
Can you provide the ChartMill fundamental rating for ARDENT HEALTH INC?
ChartMill assigns a fundamental rating of 6 / 10 to ARDT.
What is the valuation status of ARDENT HEALTH INC (ARDT) stock?
ChartMill assigns a valuation rating of 9 / 10 to ARDENT HEALTH INC (ARDT). This can be considered as Undervalued.
Can you provide the profitability details for ARDENT HEALTH INC?
ARDENT HEALTH INC (ARDT) has a profitability rating of 6 / 10.
What is the expected EPS growth for ARDENT HEALTH INC (ARDT) stock?
The Earnings per Share (EPS) of ARDENT HEALTH INC (ARDT) is expected to grow by 52.55% in the next year.